New immunotherapy could stop progression of Parkinson’s disease

OHSU part of expanded clinical trial measuring effectiveness

By Erik Robinson June 18, 2018 Portland, Oregon

Downloads

Joseph Quinn, M.D., professor of neurology in the OHSU School of Medicine and director of OHSU’s Parkinson Disease and Movement Disorders Program, (right) examines a patient with Parkinson's disease, June 14, 2018. (OHSU/Kristyna Wentz-Graff)

Parkinson's disease treatment

Joseph Quinn, M.D., professor of neurology in the OHSU School of Medicine and director of OHSU’s Parkinson Disease and Movement Disorders Program, (right) examines a patient with Parkinson's disease, June 14, 2018. (OHSU/Kristyna Wentz-Graff)

Parkinson's disease treatment

Joseph Quinn, M.D., professor of neurology in the OHSU School of Medicine and director of OHSU’s Parkinson Disease and Movement Disorders Program, (right) examines a patient with Parkinson's disease, June 14, 2018. (OHSU/Kristyna Wentz-Graff)

Joseph Quinn OHSU 2016

Joseph Quinn, M.D. 2016. (OHSU)